BioTrinity 2016, the 10th edition, hosted more than a thousand executives and investors from the life sciences sector
4th May 2016, London, UK: OBN – the membership organisation supporting the UK’s innovative life sciences companies - announces today that BioTrinity, its annual conference and 10th edition this year, has once again confirmed its position as Europe’s leading investment and biopartnering conference, with 1020 delegates present, building on its growing momentum and success in the sector.
John Harris, CEO of OBN, commented on this year’s event : “For its 10th edition, BioTrinity has been a fabulous success. The large number of delegates from across Europe, with a record number of investors and extremely high calibre panellists, confirms BioTrinity’s position as a key meeting in the European life sciences calendar. We would like to thank all our sponsors and speakers and already look forward to the 11th edition in 2017.”
The success of BioTrinity 2016 is demonstrated by the outstanding statistics:
• 1020 delegates from over 637 companies from more than 30 countries across Europe, Asia and North America
• Participation of more than 181 investors specialising in funding emerging biotechnology and life sciences companies as well as more than 60 pharmaceutical company delegates
• 91 company pitches for partners and investment among 204 speakers throughout the two-day conference
• This year saw 2518 one-to-one partnering meetings scheduled
• A new Perfect Pitch session with 9 life science companies pitching to a floor of experienced investors
• Hosting one of Europe’s largest life sciences investment lunch
Scott C. Brun, Vice President, Corporate Strategy Office at AbbVie Ventures, comments: "AbbVie is proud to be a sponsor of the BioTrinity 2016 investment and biopartnering conference. Our team found the meeting to be an effective way to network with proven investors and cutting edge entrepreneurs in order to strengthen relationships and jointly identify emerging science with the potential to transform care in our core areas of oncology, immunologic, and neurodegenerative diseases.”
4th May 2016, London, UK: OBN – the membership organisation supporting the UK’s innovative life sciences companies - announces today that BioTrinity, its annual conference and 10th edition this year, has once again confirmed its position as Europe’s leading investment and biopartnering conference, with 1020 delegates present, building on its growing momentum and success in the sector.
John Harris, CEO of OBN, commented on this year’s event : “For its 10th edition, BioTrinity has been a fabulous success. The large number of delegates from across Europe, with a record number of investors and extremely high calibre panellists, confirms BioTrinity’s position as a key meeting in the European life sciences calendar. We would like to thank all our sponsors and speakers and already look forward to the 11th edition in 2017.”
The success of BioTrinity 2016 is demonstrated by the outstanding statistics:
• 1020 delegates from over 637 companies from more than 30 countries across Europe, Asia and North America
• Participation of more than 181 investors specialising in funding emerging biotechnology and life sciences companies as well as more than 60 pharmaceutical company delegates
• 91 company pitches for partners and investment among 204 speakers throughout the two-day conference
• This year saw 2518 one-to-one partnering meetings scheduled
• A new Perfect Pitch session with 9 life science companies pitching to a floor of experienced investors
• Hosting one of Europe’s largest life sciences investment lunch
Scott C. Brun, Vice President, Corporate Strategy Office at AbbVie Ventures, comments: "AbbVie is proud to be a sponsor of the BioTrinity 2016 investment and biopartnering conference. Our team found the meeting to be an effective way to network with proven investors and cutting edge entrepreneurs in order to strengthen relationships and jointly identify emerging science with the potential to transform care in our core areas of oncology, immunologic, and neurodegenerative diseases.”
